Claim Ledger
86% answered
Did management answer the analysts?
12 analyst questions audited.
View Claim Ledger →Archean Chemical Industries Limited — Q4 FY26
Archean Chemical's Q4 FY26 standalone revenue fell 9% YoY to ₹304.7 crore, with EBITDA down 34.3% to ₹66.4 crore and margin at 21.79%.
bearish
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Archean Chemical's Q4 FY26 standalone revenue fell 9% YoY to ₹304.7 crore, with EBITDA down 34.3% to ₹66.4 crore and margin at 21.79%. Industrial salt volumes dropped 7.2% to 1.1 million tons due to customer deferrals from the US-Iran conflict and logistics disruptions from road construction in Kutch, adding ₹14-15 crore in extra costs. Bromine volumes recovered to 3,731 tons (+4% YoY) with realization up 14%, but long-term contract pricing lagged spot. The bromine derivatives business grew 50% YoY but remains at 45% capacity utilization. Management expects logistics normalization by early Q3 FY27 and aims to restore historical margins as external headwinds subside. Key risk: sustained geopolitical tensions could keep commodity and freight costs elevated, delaying margin recovery.
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Sustained geopolitical tensions (US-Iran conflict)
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Industrial Salt Volume
1.1M tons
-7.2% YoY
Q4 volume impacted by customer deferrals and logistics issues; full year volume up 22% to 4.22M tons.
Bromine Volume
3,731 tons
+4% YoY
Production recovered to historical daily rates of ~55 tons per day by mid-February.
Bromine Realization
+14% YoY
+14% YoY
Pricing actions on select contracts; majority of long-term contracts renegotiated upward.
Bromine Derivatives Revenue
₹23.8 crore
+50% YoY
Full year revenue up ~300% YoY; capacity utilization still at 45%.
What Changed vs Last Quarter
NEW
Bromine production growth target of 15% YoY in FY27
Management targets ~15% volume growth in bromine production for FY27, aiming to reach ~25,000 tons annualized.
NEW
Logistics cost normalization by early Q3 FY27
Road construction in Kutch expected to complete by early Q3 FY27, reducing transportation distance and costs.
NEW
Historical margin recovery as external factors stabilize
Management expects EBITDA margins to return to historical levels once logistics and commodity costs normalize.
DROPPED
Bromine derivatives utilization target of 60-70% in FY27
Management expects to scale up bromine derivatives utilization from current 30-40% to 60-70% by end of FY27, driven by new product pipeline and customer approvals.
DROPPED
Bromine production to reach 18,000 tons run rate in FY27
Management stated they will be 'north of 18,000 tons' of bromine production next year, recovering from operational disruptions.
DROPPED
SOP plant-scale trials in Q4 FY26, meaningful contribution in H2 FY27
SOP pilot trials successful; plant-scale trials to commence in Q4 FY26, with meaningful revenue expected in second half of FY27.
DROPPED
Flame retardant project timeline of 12-18 months maintained
The flame retardant bromine project is under evaluation but remains on track for a 12-18 month timeline from Q2 FY26, targeting end of FY27.
NEW RISK
Sustained geopolitical tensions (US-Iran conflict)
Continued conflict could keep freight and commodity costs elevated, delaying margin recovery.
NEW RISK
Bromine derivatives ramp-up slower than expected
Capacity utilization remains at 45% due to product development delays and pricing pressure; analyst questioned if FY27 targets are achievable.
NEW RISK
Industrial salt pricing pressure from new capacity
New salt capacity in Australia and Middle East adds competitive intensity, pressuring realizations.
NEW RISK
Orin Hydrocarbons (mud chemicals) revenue guidance at risk
Gujarat plant awaiting government approvals; product roadmap redefined; analyst noted 150 crore revenue target may be delayed.
RISK GONE
Persistent delays in SOP and derivatives ramp-up
SOP and bromine derivatives have faced repeated delays; management acknowledged being 12-18 months behind on derivatives. Further delays could impact FY27 revenue expectations.
RISK GONE
Bromine production constraints from weather and brine quality
Operational disruptions from erratic monsoons and brine quality changes have constrained bromine output. While fixes are implemented, recurrence could limit volume growth.
RISK GONE
Margin pressure from rising bromine costs on derivatives
Increasing bromine prices are squeezing margins in the derivatives segment as cost pass-through is limited. This could persist if bromine prices remain elevated.
RISK GONE
Execution risk in semiconductor project (Systm)
The Systm semiconductor project depends on finalizing a fiscal support agreement with the Indian Semiconductor Mission, which has no clear end date. Delays could push back revenue generation.
🤫 Topics management stopped discussing
Mentioned in Q2 FY26, Q3 FY26
Management expects to scale up bromine derivatives utilization from current 30-40% to 60-70% by end of FY27, driven by new product pipeline and customer approvals.
Mentioned in Q2 FY26, Q3 FY26
The Systm semiconductor project depends on finalizing a fiscal support agreement with the Indian Semiconductor Mission, which has no clear end date. Delays could push back revenue generation.
Fast read
Guidance and risk preview
Management targets ~15% volume growth in bromine production for FY27, aiming to reach ~25,000 tons annualized.
Continued conflict could keep freight and commodity costs elevated, delaying margin recovery.
View Risks →